This article is more than 5 years old. Information may no longer be current.
NICE gives preliminary recommendation to Ozurdex for DME
The National Institute for Health and Care Excellence has recommended Allergan’s Ozurdex intravitreal dexamethasone implant for the treatment of diabetic macular edema in preliminary technology appraisal guidance, according to an agency release.
The organization limited its recommendation to use in aphakic eyes in patients whose diabetic macular edema does not respond to non-corticosteroid treatment or for whom non-corticosteroid treatment is not suitable.
The implant has marketing authorization in the UK for treatment of adult patients with visual impairment due to diabetic macular edema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for, non-corticosteroid therapy, the release said.
The Scottish Medicines Consortium is due to publish advice in May on use of the implant for treatment of visual impairment due to diabetic macular edema, the release said.